Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GOAL-RCT: Colesevelam vs Ezetimibe in T2DM
NCT02682680Phase 4Completed
- Sponsor
- LMC Diabetes & Endocrinology
- Start
- Jan 2016
- Primary completion
- May 2017
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of colesevelam in type 2 diabetes mellitus (T2DM) and hypercholesterolemia (2 arms), sponsored by LMC Diabetes & Endocrinology. Primary endpoint: Proportion of subjects who achieve target HbA1c and LDL cholesterol at 24 weeks. Started Jan 2016; status: completed.
02
Drugs
colesevelam
03
Conditions
type 2 diabetes mellitus (T2DM)hypercholesterolemia
Beyond the preview
Go deeper on NCT02682680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02682680.